K. Bouzid

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 83 citations · Full text

A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer

K. Bouzid, S. Khalfallah, Jerzy Tujakowski et al. · Annals of Oncology · 2003 · 21 citations

First-line Therapy, Medicine, Pharmacology +7

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

Khalid Alsaleh, Heba Al Zahwahry, A. Bounedjar et al. · Journal of Cancer Research and Clinical Oncology · 2023 · 14 citations · Full text

Endocrine Oncology, Oncology, Neoadjuvant Endocrine Therapy +8

A phase III trial of taxotere and doxorubicin (AT) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) in patients with unresectable locally advanced breast cancer: an interim analysis

K. Bouzid, J. Vinholes, Fernando Palacios Salas et al. · European Journal of Cancer · 2001 · 10 citations

Interim Analysis, Advanced Breast Cancer, Breast Oncology +8

Epidemiology of breast cancer in women based on diagnosis data from oncologists and senologists in Algeria

F. Smaili, Abdelkader El Hakim Boudjella, Adlane Dib et al. · Cancer Treatment and Research Communications · 2020 · 10 citations · Full text